Last reviewed · How we verify
EYE103
At a glance
| Generic name | EYE103 |
|---|---|
| Also known as | Restoret |
| Sponsor | EyeBiotech Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME (PHASE2, PHASE3)
- A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) (PHASE1, PHASE2)
- A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO (PHASE2)
- A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |